TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02922985
Drug: Intravenous acetominophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose if 1 gram intravenous to be given pre-surgery
Study: NCT02922985
Drug: Ketorolac, intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of 60 mg Intramuscular to be given at time of skin closure
Study: NCT02922985
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
Study: NCT00063817
Drug: Conditioning Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
Study: NCT03241264
Drug: ND-L02-s0201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified day
Study: NCT01053637
Drug: hydrocodone/acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
Study: NCT00003050
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003050
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01147211
Drug: MK2206
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
Study: NCT02385240
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02311673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT04315350
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone is given together with curcumin-placebo
Study: NCT02988050
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil used for conscious sedation.
Study: NCT02988050
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: With local anaesthetic for skin infiltration.
Study: NCT02349425
Drug: Placebo (for gefapixant)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to gefapixant 7.5 and 50mg tablets administered orally
Study: NCT00616902
Drug: Placebo Injection 4 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
Study: NCT04703205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: Placebo without ivermectin as an ingredient, single oral administration on Day 1 (fasting state)
Study: NCT02325713
Drug: Cysticide
Normalized name: Crystacide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
Study: NCT02325713
Drug: Cysticide
Normalized name: Crystacide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
Study: NCT03301155
Drug: Anaferon for children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT03301155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT00448201
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 5 mg/m\^2 per day on days +1, +3 and +6
Study: NCT03918239
Drug: SHP643
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive injection of SHP643.
Study: NCT02548975
Drug: Statin, beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving either statin or beta blockers prior to cardiac surgery.
Study: NCT00196989
Drug: GW677954
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01492179
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline would be administered intravenously and intra-abdominally.
Study: NCT04505839
Drug: STP1002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule, QD
Study: NCT04640831
Drug: 5 Methoxy N,N Dimethyltryptamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH001 administered via inhalation
Study: NCT02564380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01519089
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Study: NCT01519089
Drug: CP-690, 550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Study: NCT00201708
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Study: NCT00201708
Drug: Cyclophosphamide (AC)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Study: NCT00685698
Drug: TG-873870 (Nemonoxacin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg
Study: NCT04239469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00040651
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03215862
Drug: Normal Saline 0.9% Infusion Solution Bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
Study: NCT01219907
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01500226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: (4 X 0 mg capsules) 0 mg PO
Study: NCT01915147
Drug: OXN PR followed by OxyPR tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05082753
Drug: Stromectol ® tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Ivermectin tablets were administered orally.
Study: NCT01986270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03788759
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo, as an adjunct to antipsychotic medication.
Study: NCT02604836
Drug: Ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated oral ibandronate tablet (150 mg) once-monthly
Study: NCT02548559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution.
Study: NCT01430234
Drug: Panzytrat 25.000 FIP-E units of Lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
Study: NCT04296266
Drug: Alda-341
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement d-limonene orally administered as a drug.
Study: NCT02653612
Drug: EC17 imaging contrast agent
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
Study: NCT02678520
Drug: Casodex, Zoladex , Lupron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months.
Study: NCT01146600
Drug: Clarithromycin followed by placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
Study: NCT01146600
Drug: Placebo then Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
Study: NCT00078000
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01929330
Drug: GI198745 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
Study: NCT00978367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
Study: NCT00978367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
Study: NCT00978367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
Study: NCT03435692
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl was administered in the operating room for induction of anesthesia. Subsequent doses in the operating room were standardized to be given only for heart rate or blood pressure increases \> 20% above baseline and occurring more than 30 minutes after the block if applicable.
Study: NCT03435692
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Acetaminophen was administered as needed for pain in the Post-Anesthesia Care Unit (PACU) and then scheduled for 72 hours.
Study: NCT01668433
Drug: Regimens (Primaquine, Methylene blue)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
Study: NCT03134378
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice daily
Study: NCT02182050
Drug: BIBF 1120 ES high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182050
Drug: Placebo to BIBF 1120 ES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01208103
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02726399
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
Study: NCT00162916
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornstarch
Study: NCT00980109
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
Study: NCT01641159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
Study: NCT00980109
Drug: placebo for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
Study: NCT01137578
Drug: Magnetic Resonance Imaging with Contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
Study: NCT04438096
Drug: 100 mg
Normalized name: urea 100 MG
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
Study: NCT04438096
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
Study: NCT04438096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three placebo pills (QD) will be orally administered for 12 weeks
Study: NCT01805765
Drug: Qing'E pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: composed of eucommia, psoralen, walnuts and garlic
Study: NCT03882580
Drug: Anti-Cancer Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
Study: NCT01594775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two-times daily self-administration of nasal spray containing placebo during five days after wounding.
Study: NCT03454126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02519140
Drug: Cook Medical EMR Gel
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
Study: NCT01518153
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
Study: NCT03775928
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1000mg/m2 bid d1-d14
Study: NCT03089138
Drug: Regan Tangjiang
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment duration is 3 consecutive days.
Study: NCT02564055
Drug: GSK2894512 0.5% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study: NCT02564055
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white vehicle cream base to be applied topically
Study: NCT02766673
Drug: Sterile Saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Study: NCT03376555
Drug: Acetylcholine (ACh) Dose Response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin
Study: NCT00625651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive dummy AMG 655 (to maintain blind)
Study: NCT00625651
Drug: Modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)
Study: NCT01714661
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms 1, 2
Study: NCT01714661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 3
Study: NCT00612872
Drug: [123I]CLINDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
Study: NCT00704899
Drug: Amitryptiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitryptiline 25mg once daily
Study: NCT00438672
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection without steroid
Study: NCT00565487
Drug: Capecitabine, Tarceva
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
Study: NCT00422812
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Placebo
Study: NCT00422812
Drug: Inhaled PCZ 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Prochlorperazine 5 mg
Study: NCT00422812
Drug: Inhaled PCZ 7.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Prochlorperazine 7.5 mg
Study: NCT00422812
Drug: Inhaled PCZ 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato Prochlorperazine 10 mg
Study: NCT03591653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02480686
Drug: SOF+PEG+RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Study: NCT00771875
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
Study: NCT04531072
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Study: NCT00652925
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher dose, 6 mg/kg/dose BID
Study: NCT00652925
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug at lower dose
Study: NCT00652925
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control comparator, 15 mg/kg/dy target dose
Study: NCT00507026
Drug: IV Diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Diclofenac q6h
Study: NCT00507026
Drug: IV ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketorolac q6h
Study: NCT00507026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo q6h
Study: NCT01453400
Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
Study: NCT01453400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
Study: NCT03345576
Drug: Testosterone and standard NMES
Normalized name: testosterone and estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
Study: NCT00982982
Drug: Placebo (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
Study: NCT01817322
Drug: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
Study: NCT01397929
Drug: BAL101553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT01254305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules, oral administration, once daily dosing